Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transdermal patch Clear all
Completed Not applicable Interventional Results available

Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking

NCT02224391
View directory record Official record
Conditions
Current Every Day Smoker
Interventions
Computer-Assisted Smoking Cessation Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Sham Intervention
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

NCT00506285
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System (MTS), placebo patch
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Results available

Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism

NCT02552147
View directory record Official record
Conditions
Autism Spectrum Disorder, Aggression, Irritability
Interventions
Transdermal nicotine, Transdermal placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting

NCT02457195
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
granisetron
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Smoking Termination / Anxiety Reduction Treatment (ST/ART)

NCT01789125
View directory record Official record
Conditions
Smoking, Anxiety Disorders
Interventions
Nicotine Patch, Smoking Termination and Anxiety Reduction Treatment, Education-Supportive Psychotherapy
Drug · Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

NCT02256540
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Climara, Placebo patch, Resveratrol, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of the Nicotine Patch in Suppressing Nicotine Withdrawal Symptoms in Women Versus Men - 1

NCT00218140
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
nicotine transdermal system
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 5:32 AM EDT
Withdrawn Phase 2 Interventional

Relapse Prevention Study in Newly Abstinent Smokers

NCT00793468
View directory record Official record
Conditions
Substance Dependence
Interventions
GSK598809, Nicotine Replacement Transdermal Patch, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
DeLand, Florida • Pembroke Pines, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Enhancing a High School Based Smoking Cessation Program

NCT01145001
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Cognitive Behavioural Therapy, Contingency Management, Nicotine Transdermal Patch
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
14 Years to 19 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 22, 2026, 5:32 AM EDT
Enrolling by invitation Not applicable Interventional

Prevention and Reduction of Falls: Testing and Evaluating Cutting Edge Haptic Technology

NCT07781397
View directory record Official record
Conditions
Fall Risk, Fall Risk, Fall Prevention, Accidental Falls, Accidental Falls/Prevention & Control
Interventions
LIBERTY Patch, Sham Patch
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Mansfield, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

NCT00796289
View directory record Official record
Conditions
Infertility
Interventions
GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 38 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults

NCT02221726
View directory record Official record
Conditions
Healthy
Interventions
JNJ-35684-AAA-023: Size 1; small patch, JNJ-35684-AAA-023: Size 2; large patch
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT03397862
View directory record Official record
Conditions
Skin Irritation, Sensitization
Interventions
Donepezil TDS, Vehicle TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 5:32 AM EDT
Suspended Phase 1 Interventional

Safety of MOON101 for the Treatment of Peanut Allergy

NCT07580898
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dose A, Dose B, Dose C, Dose D, Dose E, Placebo
Combination Product
Lead sponsor
Moonlight Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

US Cycle Control and Blood Pressure Study

NCT00920985
View directory record Official record
Conditions
Contraception
Interventions
Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Patch Study - Intervention for HIV Positive Smokers

NCT02982772
View directory record Official record
Conditions
Smoking Cessation, HIV
Interventions
Combination Therapy, Standard Care Intervention
Other
Lead sponsor
dr. maria miguez
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 4 Interventional

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

NCT04150614
View directory record Official record
Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

NCT00792103
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 22, 2026, 5:32 AM EDT